NCT07782632 Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
| NCT ID | NCT07782632 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anhui Provincial Hospital |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 467 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 467 participants in total. It began in 2019-01-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy. The study explores whether baseline liver volume metrics can effectively predict survival outcomes and treatment responses in this patient population to assist in clinical decision-making.
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years. * Clinically or histologically confirmed unresectable hepatocellular carcinoma (HCC). * Received immunotherapy as part of their tumor treatment regimen. * Availability of high-quality baseline pre-treatment imaging data suitable for functional liver volume and total liver volume segmentation. * Complete clinical and follow-up survival data. Exclusion Criteria: * \- Prior surgical resection or liver transplantation for HCC. * Co-existence of other concurrent primary malignant tumor types. * Severe image artifacts or technical limitations that prevent robust liver volume quantification. * Incomplete medical records, missing key baseline clinical data, or loss to follow-up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07782632 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07782632 currently recruiting?
Yes, NCT07782632 is actively recruiting participants. Contact the research team at wangjoe@ustc.edu.cn for enrollment information.
Where is the NCT07782632 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT07782632 clinical trial?
NCT07782632 is sponsored by Anhui Provincial Hospital. The trial plans to enroll 467 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.